Last reviewed · How we verify
Crisaborole 2% Cream
At a glance
| Generic name | Crisaborole 2% Cream |
|---|---|
| Also known as | Eucrisa |
| Sponsor | Jinnah Postgraduate Medical Centre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema (PHASE4)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crisaborole 2% Cream CI brief — competitive landscape report
- Crisaborole 2% Cream updates RSS · CI watch RSS
- Jinnah Postgraduate Medical Centre portfolio CI